Capital Impact Advisors LLC Lowers Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Capital Impact Advisors LLC reduced its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) by 47.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,301 shares of the biopharmaceutical company’s stock after selling 53,776 shares during the period. Catalyst Pharmaceuticals comprises about 0.9% of Capital Impact Advisors LLC’s holdings, making the stock its 16th largest holding. Capital Impact Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $907,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of CPRX. FMR LLC boosted its holdings in Catalyst Pharmaceuticals by 24.2% in the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 822 shares during the period. Covestor Ltd boosted its holdings in Catalyst Pharmaceuticals by 768.0% in the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,316 shares during the period. Quantbot Technologies LP purchased a new position in Catalyst Pharmaceuticals in the first quarter valued at $62,000. KBC Group NV purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at $106,000. Finally, Point72 Hong Kong Ltd boosted its holdings in Catalyst Pharmaceuticals by 63.0% in the first quarter. Point72 Hong Kong Ltd now owns 9,670 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 3,738 shares during the period. 86.66% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $15.75 on Friday. The business’s 50-day simple moving average is $16.48 and its 200-day simple moving average is $15.58. Catalyst Pharmaceuticals, Inc. has a one year low of $6.15 and a one year high of $22.11. The stock has a market capitalization of $1.64 billion, a P/E ratio of 25.82 and a beta of 1.16.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. StockNews.com started coverage on Catalyst Pharmaceuticals in a report on Thursday. They issued a “buy” rating for the company. Truist Financial lifted their price target on Catalyst Pharmaceuticals from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, January 19th. HC Wainwright lifted their price target on Catalyst Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, December 21st. Finally, Piper Sandler lifted their price target on Catalyst Pharmaceuticals from $20.00 to $21.00 in a report on Tuesday, February 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $20.63.

Catalyst Pharmaceuticals Profile

(Get Rating)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms.